EP3600393A4 - Polythérapie pour le traitement de cancers solides et hématologiques - Google Patents

Polythérapie pour le traitement de cancers solides et hématologiques Download PDF

Info

Publication number
EP3600393A4
EP3600393A4 EP18771103.1A EP18771103A EP3600393A4 EP 3600393 A4 EP3600393 A4 EP 3600393A4 EP 18771103 A EP18771103 A EP 18771103A EP 3600393 A4 EP3600393 A4 EP 3600393A4
Authority
EP
European Patent Office
Prior art keywords
solid
treatment
combination therapy
hematological cancers
hematological
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP18771103.1A
Other languages
German (de)
English (en)
Other versions
EP3600393A1 (fr
Inventor
Pamela T. Manning
Robyn PURO
Juan C. Almagro
Robert W. KARR
Benjamin J. CAPOCCIA
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Arch Oncology Inc
Original Assignee
Arch Oncology Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US15/871,802 external-priority patent/US20180142019A1/en
Application filed by Arch Oncology Inc filed Critical Arch Oncology Inc
Publication of EP3600393A1 publication Critical patent/EP3600393A1/fr
Publication of EP3600393A4 publication Critical patent/EP3600393A4/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
EP18771103.1A 2017-03-22 2018-03-22 Polythérapie pour le traitement de cancers solides et hématologiques Withdrawn EP3600393A4 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201762475032P 2017-03-22 2017-03-22
US201762475036P 2017-03-22 2017-03-22
US15/871,802 US20180142019A1 (en) 2016-10-21 2018-01-15 Therapeutic cd47 antibodies
PCT/US2018/023860 WO2018175790A1 (fr) 2017-03-22 2018-03-22 Polythérapie pour le traitement de cancers solides et hématologiques

Publications (2)

Publication Number Publication Date
EP3600393A1 EP3600393A1 (fr) 2020-02-05
EP3600393A4 true EP3600393A4 (fr) 2020-12-23

Family

ID=63585757

Family Applications (1)

Application Number Title Priority Date Filing Date
EP18771103.1A Withdrawn EP3600393A4 (fr) 2017-03-22 2018-03-22 Polythérapie pour le traitement de cancers solides et hématologiques

Country Status (7)

Country Link
EP (1) EP3600393A4 (fr)
JP (1) JP7170331B2 (fr)
CN (1) CN111148535A (fr)
AU (1) AU2018240377A1 (fr)
CA (1) CA3057139A1 (fr)
SG (1) SG11201908602UA (fr)
WO (1) WO2018175790A1 (fr)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9221908B2 (en) 2012-12-12 2015-12-29 Vasculox, Inc. Therapeutic CD47 antibodies
BR112015013431A2 (pt) 2012-12-12 2017-11-14 Vasculox Inc anticorpos monoclonais ou respectivos fragmentos ligantes de antígenos, composição farmacêutica, e usos de anticorpo monoclonal ou respectivo fragmento ligante de antígenos
RU2748401C2 (ru) 2015-09-18 2021-05-25 Арч Онколоджи, Инк. Терапевтические антитела к CD47
WO2018075960A1 (fr) 2016-10-21 2018-04-26 Tioma Therapeutics, Inc. Anticorps cd47 thérapeutiques
EP3892637A1 (fr) * 2018-12-03 2021-10-13 Shanghai Pharmaexplorer Co., Ltd. Anticorps cd47, son procédé de préparation et ses applications
EP3969120A4 (fr) * 2019-05-16 2023-09-13 Arch Oncology, Inc. Compositions thérapeutiques et méthodes de traitement du cancer en combinaison avec des analogues de protéines d'interleukine
EP3980747A1 (fr) 2019-06-07 2022-04-13 ALX Oncology Inc. Procédés et réactifs pour réduire les interférences de médicaments se liant au cd47 dans des dosages sérologiques
CN114901364A (zh) * 2019-10-23 2022-08-12 安驰肿瘤公司 用于治疗实体癌和血液癌的组合疗法
CN115397853A (zh) 2019-12-17 2022-11-25 辉瑞大药厂 对cd47、pd-l1具特异性的抗体及其用途
EP4256336A1 (fr) 2020-12-06 2023-10-11 ALX Oncology Inc. Multimères pour réduire l'interférence de médicaments qui se lient à cd47 dans des dosages sérologiques

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040073013A1 (en) * 1999-03-10 2004-04-15 Naoshi Fukushima Polypeptide inducing apoptosis
WO2014123580A1 (fr) * 2013-02-06 2014-08-14 Inhibrx Llc Anticorps cd47 n'induisant ni l'appauvrissement en globules rouges ni l'appauvrissement en plaquettes
WO2017049251A2 (fr) * 2015-09-18 2017-03-23 Tioma Therapeutics, Inc. Anticorps cd47 thérapeutiques

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8101719B2 (en) * 2003-11-11 2012-01-24 Chugai Seiyaku Kabushiki Kaisha Humanized anti-CD47 antibody
ES2639857T3 (es) * 2008-02-11 2017-10-30 Cure Tech Ltd. Anticuerpos monoclonales para el tratamiento del tumor
CN102812041A (zh) * 2010-01-21 2012-12-05 英穆尔诺基公司 治疗卵巢癌的组合物及方法
MX360772B (es) * 2012-02-06 2018-11-15 Inhibrx Inc Anticuerpos cd47 y metodos de uso de los mismos.
AU2013278843A1 (en) * 2012-06-21 2014-03-27 Compugen Ltd. LSR antibodies, and uses thereof for treatment of cancer
US9221908B2 (en) * 2012-12-12 2015-12-29 Vasculox, Inc. Therapeutic CD47 antibodies

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040073013A1 (en) * 1999-03-10 2004-04-15 Naoshi Fukushima Polypeptide inducing apoptosis
WO2014123580A1 (fr) * 2013-02-06 2014-08-14 Inhibrx Llc Anticorps cd47 n'induisant ni l'appauvrissement en globules rouges ni l'appauvrissement en plaquettes
WO2017049251A2 (fr) * 2015-09-18 2017-03-23 Tioma Therapeutics, Inc. Anticorps cd47 thérapeutiques

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
ANA-CAROLINA MARTINEZ-TORRES ET AL: "CD47 Agonist Peptides Induce Programmed Cell Death in Refractory Chronic Lymphocytic Leukemia B Cells via PLC[gamma]1 Activation: Evidence from Mice and Humans", PLOS MEDICINE, vol. 12, no. 3, 3 March 2015 (2015-03-03), pages e1001796, XP055318218, DOI: 10.1371/journal.pmed.1001796 *
JESSICA LO ET AL: "Anti-CD47 antibody suppresses tumour growth and augments the effect of chemotherapy treatment in hepatocellular carcinoma", LIVER INTERNATIONAL, vol. 36, no. 5, 1 May 2016 (2016-05-01), GB, pages 737 - 745, XP055505901, ISSN: 1478-3223, DOI: 10.1111/liv.12963 *
KATHAWALA: "Abstract 4001: The anti-CD47 antibody Hu5F9-G4 activates macrophages and inhibits ovarian cancer xenografts, alone and in combination with chemotherapy or immunotherapy | Cancer Research", AACR 107TH ANNUAL MEETING 2016, vol. 76, 15 July 2016 (2016-07-15), XP055506116, DOI: 10.1158/1538-7445.AM2016-4001 *
PARTHA MANNA ET AL: "CD47 mediates killing of breast tumor cells via Gi-dependent inhibition of protein kinase A.", CANCER RESEARCH, vol. 64, no. 3, 1 February 2004 (2004-02-01), pages 1026 - 1036, XP055030076, ISSN: 0008-5472, DOI: 10.1158/0008-5472.CAN-03-1708 *
PER-ARNE OLDENBORG: "CD47: A cell surface glycoprotein which regulates multiple functions of hematopoietic cells in health and disease", ISRN HEMATOLOGY, 1 January 2013 (2013-01-01), pages 1 - 19, XP055663144, DOI: 10.1155/2013/614619 *
ROBERT W KARR: "Experimental data on anti-CD47 antibodies", OPPOSITION PROCEEDINGS RELATING TO EUROPEAN PATENT EP2242512, 20 January 2017 (2017-01-20), pages 1 - 11, XP055692350, Retrieved from the Internet <URL:https://register.epo.org/application?number=EP09701993&lng=en&tab=doclist> [retrieved on 20200506] *
See also references of WO2018175790A1 *
XIAOJUAN LIU ET AL: "CD47 blockade triggers T cell-mediated destruction of immunogenic tumors", NATURE MEDICINE, vol. 21, no. 10, 31 October 2015 (2015-10-31), New York, pages 1209 - 1215, XP055478072, ISSN: 1078-8956, DOI: 10.1038/nm.3931 *

Also Published As

Publication number Publication date
SG11201908602UA (en) 2019-10-30
AU2018240377A1 (en) 2019-10-31
CN111148535A (zh) 2020-05-12
WO2018175790A1 (fr) 2018-09-27
EP3600393A1 (fr) 2020-02-05
JP7170331B2 (ja) 2022-11-14
JP2020511481A (ja) 2020-04-16
CA3057139A1 (fr) 2018-09-27

Similar Documents

Publication Publication Date Title
EP3600393A4 (fr) Polythérapie pour le traitement de cancers solides et hématologiques
EP3600281A4 (fr) Traitement d&#39;association pour le traitement ou la prévention de tumeurs
EP3490581A4 (fr) Compositions neuromodulatrices et méthodes associées de traitement du cancer
EP3325473A4 (fr) Composés et leurs utilisations dans le traitement de cancers et d&#39;autres états médicaux
EP3585389A4 (fr) Traitement du cancer entraîné par egfr avec moins d&#39;effets secondaires
EP3894392A4 (fr) Compositions et procédés pour le traitement du cancer
EP3565558A4 (fr) Polythérapie pour le traitement du cancer
EP3307240A4 (fr) Polythérapie pour le traitement du cancer
EP3359192A4 (fr) Polythérapie pour le traitement du cancer
EP3580560A4 (fr) Méthodes pour la détection et le traitement du cancer du poumon
ZA201900960B (en) Methods and compositions for the treatment of cancer
EP3558279A4 (fr) Compositions et méthode s pour le traitement d&#39;une douleur chronique
EP3615056A4 (fr) Méthodes et compositions pour le dépistage et le traitement du cancer
EP3490561A4 (fr) Combinaisons pour le traitement du cancer
EP3503887A4 (fr) Combinaisons pour le traitement du cancer
EP3478284A4 (fr) Composés et compositions pour le traitement du cancer
IL280587B (en) Fluorocitidine derivatives and their preparations for use in cancer treatment
EP4048406A4 (fr) Polythérapie pour le traitement de cancers solides et hématologiques
EP3860610A4 (fr) Polythérapie pour le traitement du cancer
EP3402527A4 (fr) Nanoparticules thérapeutiques pour le traitement du neuroblastome et d&#39;autres cancers
EP3820492A4 (fr) Apmv et utilisations associées pour le traitement du cancer
EP3897650A4 (fr) Polythérapie pour le traitement du cancer
IL266993A (en) Combined therapy for cancer treatment
EP3688023A4 (fr) Méthodes et compositions pour le traitement du cancer
IL272147A (en) Methods and preparations for the treatment of cancer

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20190920

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
REG Reference to a national code

Ref country code: DE

Ref legal event code: R079

Free format text: PREVIOUS MAIN CLASS: A61K0039000000

Ipc: C07K0016280000

A4 Supplementary search report drawn up and despatched

Effective date: 20201125

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 39/395 20060101ALI20201119BHEP

Ipc: A61K 35/28 20150101ALI20201119BHEP

Ipc: C07K 16/28 20060101AFI20201119BHEP

Ipc: C12N 5/0786 20100101ALI20201119BHEP

P01 Opt-out of the competence of the unified patent court (upc) registered

Effective date: 20230503

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

17Q First examination report despatched

Effective date: 20230705

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20231116